Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04891861
Other study ID # ML42205
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date July 1, 2021
Est. completion date July 1, 2023

Study information

Verified date May 2021
Source University of Texas at Austin
Contact Truman J Milling, MD
Phone 5124969742
Email tmilling@ascension.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized pilot trial of restarting DOACs at 1 week versus 4 weeks after traumatic intracranial hemorrhage


Description:

Restart TICrH two-center pilot trial will assign patients with anticoagulant-associated traumatic intracranial hemorrhage to restart anticoagulation at 1 week or 4 weeks. Entry into the trial is primarily driven pragmatically by clinician intent to restart any Direct Oral Anticoagulant (DOAC, i.e. apixaban, rivaroxaban, edoxaban, dabigatran. There is no head to head evidence of superiority of any drug) after anticoagulant-associated traumatic intracranial hemorrhage and equipoise concerning restart of anticoagulation at the specified time intervals. DOAC will be at label dose with label adjustments for creatinine clearance. DOAC will be at continuation dose, i.e. not initial therapy high doses in the setting of VTE.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date July 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria: 1. Acute traumatic intracranial hemorrhage on anticoagulation for Atrial Fibrillation (AF) or Venous Thromboembolism (VTE) 2. Patient is higher risk for stroke or other thrombotic events as witnessed by having a CHA2DS2-VASc score of > 3 (at least 3 of the following risk factors: age greater than 65, (age > 75 counts for 2 points), history of stroke or TIA (2 points), history of heart failure, history of diabetes, history of atherosclerotic vascular disease, female biological sex, history of hypertension) 3. DOAC prescribed at label dose with creatinine clearance adjustments. DOAC at continuation dose, i.e., not initial therapy high doses in the setting of VTE Exclusion Criteria: 1. Mechanical Valve or Ventricular Assist Device (VAD) 2. SDH >8 mm maximum width or any midline shift at any time point or more than one SDH 3. Physician plan to start/restart antiplatelet therapy during trial period 4. Abbreviated Injury Scale other than head >3 5. Pregnancy 6. Inability to understand need for adherence to study protocol 7. Renal function below DOAC label exclusions 8. Any active pathological bleeding (e.g. no acute blood on most recent CT) 9. Hypersensitivity to drug or other label contraindication 10. Any bleeding that the investigator deems unsafe to restart DOAC at 1 week post injury, or conversely unsafe to hold DOAC to 4 weeks 11. Completion of DOAC therapy expected prior to 60 day primary endpoint, e.g. 3-6 month VTE treatment 12. Concomitant need for strong inducers/inhibitors of p-gp and CYP3A4 13. Low body weight (<45kg) 14. Inability to swallow

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Apixaban
Direct Oral Anticoagulation all at label dose and frequency

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Texas at Austin University of Kansas

References & Publications (1)

Milling TJ Jr, Warach S, Johnston SC, Gajewski B, Costantini T, Price M, Wick J, Roward S, Mudaranthakam D, Dula AN, King B, Muddiman A, Lip GYH. Restart TICrH: An Adaptive Randomized Trial of Time Intervals to Restart Direct Oral Anticoagulants after Tra — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 60-day composite endpoint A 60-day composite endpoint that includes the following clinical events: New or expansion of intracranial hemorrhage, other BARC3a or above major hemorrhage 28, stroke, systemic embolism, myocardial infarction, proximal lower extremity deep vein thrombosis, pulmonary embolism and cardiovascular death 60 days
Secondary Disability Rating Scale (0-29 scale range) Functional Measure 60 days
Secondary Modified Rankin Scale (0-6 scale range) Functional Measure 60 day
Secondary Standard Gamble The standard gamble is the gold standard for analysis of decision making under uncertainty 7. It is an interview technique that begins with a description of a disease state. The patient is then asked to imagine suffering the disease and having a choice between taking a medication that might cure them but also might kill them. The so-called ping-pong method requires the interviewer to start with a hypothetical scenario of 0% probability of cure and 100% probability of a painless instant death. The interviewer then asks the patient if they would take the medication. He then flips the scenario, 100% cure, 0% death. He then goes back and forth between successive scenarios of lower death higher cure and lower cure higher death. Eventually, the patient settles at an equipoise and indecision of whether the risk of dying is worth incurring to take the medication and cure the disease. This is the patient's utility for that disease, expressed as a number between 0 and 1. pre-randomization (The day before randomization, which must occur within 6 days of index injury) and after endpoints (the day after one of the endpoints occurs. We cannot know precisely when this will occur in the 60 day follow up period)
See also
  Status Clinical Trial Phase
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Not yet recruiting NCT04849312 - Prediction of 30-Day Readmission Using Machine Learning
Active, not recruiting NCT04784351 - Prediction of Expected Length of Hospital Stay Using Machine Learning
Active, not recruiting NCT05045742 - Prediction of Patient Deterioration Using Machine Learning
Recruiting NCT03885180 - Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy N/A
Completed NCT03203759 - Hospital-Level Care at Home for Acutely Ill Adults N/A
Not yet recruiting NCT05705076 - Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis N/A
Recruiting NCT03524222 - Home Hospital for Suddenly Ill Adults N/A
Completed NCT04531280 - Rural Home Hospital: Proof of Concept N/A
Recruiting NCT06341231 - Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
Completed NCT03926780 - Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi Phase 3
Completed NCT04080570 - Remote Physician Care for Home Hospital Patients N/A
Not yet recruiting NCT03217799 - Noninvasive Measurement of Blood Coagulation N/A